ABVC BioPharma Strengthens Investment in AiBtl BioPharma with Equity Conversion and Up to $20 Million Commitment
ABVC BioPharma's strategic equity conversion and investment in AiBtl BioPharma underscores its commitment to advancing CNS drug candidates and leveraging a capital-light strategy for future growth.
